AEON Biopharma (AEON) Other Non-Current Liabilities (2021 - 2026)

AEON Biopharma has reported Other Non-Current Liabilities for 5 years, with the latest figure at $14.9 million in Q4 2025.

• Quarterly Other Non-Current Liabilities rose 1153.5% year-over-year to $14.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.9 million (up 1153.5% YoY) and the FY2025 annual result came in at $14.9 million, up 1153.5% from the prior year.
• Other Non-Current Liabilities rose to $14.9 million in Q4 2025 per AEON's latest filing, from $2.3 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $168.1 million in Q1 2024 and troughed at $306611.0 in Q1 2023.
• A 5-year average of $23.7 million and a median of $2.7 million in 2021 frame the typical range for Other Non-Current Liabilities.
• The widest YoY moves for Other Non-Current Liabilities: up 54731.37% in 2024, down 98.86% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $7.4 million in 2021, then soared by 1677.87% to $131.3 million in 2022, then retreated by 20.52% to $104.4 million in 2023, then slumped by 98.86% to $1.2 million in 2024, then soared by 1153.5% to $14.9 million in 2025.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $14.9 million, $2.3 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.